Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7621MR)

This product GTTS-WQ7621MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7621MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14391MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ5618MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP791
GTTS-WQ9279MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMMU-132
GTTS-WQ563MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 62-71-3
GTTS-WQ1923MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AGN 150998
GTTS-WQ3108MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA APN311
GTTS-WQ6718MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DS 1024
GTTS-WQ10181MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LC1004-002
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW